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Chapter 1: Introduction 
 
 Tissue engineering was once categorized as a sub-field of biomaterials, but 
has recently grown into a field of its own. It uses a combination of cells, engineering, 
and materials to improve or replace biological functions. Tissue engineering has 
been defined as an interdisciplinary field that applies the principles of engineering 
and life sciences towards the development of biological substitutes that restore, 
maintain, or improve tissue function or a whole organ1. It is understanding the 
principles of tissue growth, and applying this to produce functional replacement 
tissue for clinical use.1  
 While most of the aim for tissue engineering is to provide clinical therapies, 
there are additional applications that can be used to provide valuable information 
for evolving research. One application pursued by our lab, and referred to as an in-
vitro blood vessel mimic (BVM), aims to use tissue-engineered constructs for in-
vitro evaluation of devices and therapies.2 This blood vessel mimic is used to test 
and evaluate intravascular devices and disease treatments. The BVM is used to 
create a bench top model for testing between in-vitro bench top testing and early 
animal test models.  
 Within the Tissue Engineering Group at Cal Poly, San Luis Obispo, there have 
been numerous advances on the original BVM model which will allow us to explore 
new approaches for creating a more physiologic in-vitro tissue engineered blood 
vessel mimic (ultimate goal). This includes the research done on the investigation of 
the effects of hyperglycemia (high glucose) on the blood vessel mimic. This BVM 
consisted of human umbilical vein endothelial cells (HUVECs) on expanded 
 polytetrafloroethlyene (ePTFE) to understand the characteristics of how HUVECs 
will react to increased hyperglycemic concentrations.
 The main reason that
cardiovascular disease. Cardiovascular disease is the class of diseases that involve 
the heart or blood vessels. One example is 
which an artery wall thickens as a result of the accumulation of fatty materials such 
as cholesterol and plaque. It is a chronic inflammatory response in the walls of the 
arteries cause by accumulation of macrophage white blood cells, and prom
low-density lipoproteins without being able to remove fats and cholesterol from the 
macrophages by high-density lipoproteins. This causes narrowing and hardening of 
the arteries, and restricts blood flow that can lead to necrosis, heart disease, st
and myocardial infarction3. 
disease.3 
 
Figure 1: Normal artery (left), artery narrowed by atherosclerotic plaque (right)
 There are many common risk factors
including high cholesterol, high blood pressure, smoking, diabetes, obesity, limited 
 
 these BVMs were developed is because of 
atherosclerosis, which is a condition in 
As a result, 1 in 3 people will die from cardiovascular 
 
 specifically for cardiovascular disease
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physical activity, age, and genetic propensity, which can all contribute to the 
accelerated onset and premature effects of atherosclerosis.4  
 A common co-morbidity, and an additional focus of this project, is diabetes. 
Diabetes is a group of metabolic diseases in which a person has high blood sugar, 
either because the body does not produce enough insulin, or because cells do not 
respond to the insulin that is produced. The high blood sugar produces the classical 
symptoms of polyuria (frequent urination), polydipsia (increased thirst), and 
polyphagia (increased hunger).  
 There are three main types of diabetes. Type 1 diabetes is characterized by 
loss of the insulin producing beta cells of the islets of Langerhans in the pancreas 
leading to insulin defiency.5 It is classified as immune-mediated, where beta cell loss 
is a T-cell mediated autoimmune attack. Most people affected are healthy and often 
are children (there are adult cases as well). There is no preventive measure against 
type 1 diabetes, so it is difficult to say who will be affected by it. 
 Type 2 diabetes is characterized by insulin resistance; it is a condition where 
cells fail to use insulin properly. In early stages of type 2 diabetes, the predominant 
abnormality is reduced insulin sensitivity, where hyperglycemia can be reversed by 
a variety of measures and medications that improve insulin sensitivity.5  
 The third type is gestational diabetes, which is similar to type 2 diabetes. It 
involves inadequate insulin secretion and responsiveness, and occurs in about 2-5% 
of all pregnancies. It is treatable and requires careful medical supervision because 
20-25% of affected women develop type 2 diabetes later in life6.  
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 Insulin is the principle hormone that regulates the uptake of glucose from the 
blood into most cells. Deficiency of insulin or the insensitivity of its receptors plays a 
central role in all forms of diabetes.  
 With regard to cardiovascular disease, including for those patients that also 
suffer from diabetes, there are different medical treatments available for 
atherosclerosis that includes different medication with altered lifestyles and 
physical intervention. These methods involve invasive replacement surgery or 
minimally invasive catheter based procedures. Physical treatments that are helpful 
in the short term include minimally invasive angioplasty procedures that include 
stents to physically expand narrowed arteries7. Angioplasty is a technique of 
mechanically widening a narrowed or obstructed blood vessel. It consists of an 
empty and collapsed balloon on a guide wire, known as a balloon catheter, which is 
passed into the narrowed locations and then inflated to a fixed size using saline 
pressure. The balloon crushes the fatty deposits, opening the blood vessel for 
improved flow. The balloon is then deflated and withdrawn. A metal stent is usually 
deployed following the dilation to help maintain proper flow and mechanical 
characteristics of the diseased vessel8. 
 
 Figure 2: Angioplasty and stent deployment into a blocked artery
 Minimally invasive treatments have shown mixed results, as past experiences 
treating simple to complex lesions
sixty percent of percutaneous coronary intervention.
diameter of the vessel lumen following intravascular procedure, and is the result of 
the cellular response to the injury 
the stent pressing against the vessel walls. 
eluting stents (DES) have been developed to reduce the effects of restenosis, 
however, continued study is required to conclusive
effectiveness of these therapies
 Diabetic patients have an increased risk of restenosis after balloon 
angioplasty, resulting in increased late morbidity and mortality, compared to non
diabetic patients.10 Bare metal stents 
improve blood circulation, but it has been shown
 
6 
 resulted in restenosis for as many as fifteen to 
9 Restenosis is the reduction in 
imparted by balloon dilation and the stresses of 
Pharmaceutical compounds and drug
ly determine the long
.9 
have been used as a method of intervention to 
 that diabetes affect the 
7 
-
-term 
-
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development of restenosis after the intervention.11 Drug eluting stents slowly 
release a drug to block cell proliferation, which, it prevents restenosis that could 
block the stented artery. They are a more effective treatment than bare metal stents, 
and have shown increased lifespan.11 Randomized, double-blind study, the 
implantation of a slow-release, polymer-based, paclitaxel-eluting stent reduced the 
risk of clinical and angiographic restenosis as compared with the implantation of a 
bare-metal stent, in patients with a wide range of previously untreated coronary 
lesions.12 
 There is an established relationship between heart disease and diabetes. 
Although the main factor behind this relationship is unknown, hyperglycemia, 
abnormal lipid metabolism, and insulin resistance, coupled with frequently 
occurring hypertension results in acceleration of the atherosclerotic process; where 
coronary artery disease is responsible for three-quarters of diabetes-related 
deaths.13 
 Stent testing for coronary artery disease must understand the rules and 
regulations that it follows by the United States Food and Drug Administration (FDA). 
Preclinical testing is necessary to show that a product to market is safe and 
effective. Some of these testing include bench top testing, in-vitro testing, and 
animal studies. Bench top testing will usually measure things such as stress and 
fatigue for medical devices to ensure that they can withstand physiologic forces 
upon it and to be sure it can maintain the mechanical integrity. In-vitro testing uses  
cells to test for biocompatibility, to be sure that the cells are able to live in the 
exposed environment. 
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 For animal studies, researchers usually study rabbits, and move to larger 
animals depending on the different factors.14 For intravascular devices, porcine 
studies often serve as the final preclinical model due to anatomical similarities.14 
Since it is relatively expensive to conduct and maintain animal testing facilities, the 
development of the BVM can be of great use and importance. It will allow 
researchers to gather more information and data at a more cost effective rate before 
progressing onto animal models. The BVM consists of a biochamber, a peristaltic 
pump, media reservoir, and connecting tubing and fittings, as illustrated in Figure 3. 
The biochamber is used as a housing unit for the intended scaffold used, it (ePTFE) 
that will act as the coronary artery. The biochamber will also contain media that will 
act as the blood, to supply the cells with nutrients. The peristaltic pump is used to 
allow for the flow of media through the system. The media reservoir supplies the 
system with media, and the connecting tubing and fittings attaches the system 
together.  
 
Figure 3: SolidWorks model of the BVM system 
 
 With cardiovascular disease being a serious threat to human life, the field of 
tissue engineering is emerging and growing rapidly with numerous discoveries and 
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inventions. The use of a stent can assist with atherosclerosis by restoring proper 
flow through diseased vessel. With the new and current research in drug eluting 
stents, research has shown promising results, increasing the life expectancy of the 
individual. Even though stents are useful, diabetic patients are at a higher risk of 
restenosis as compared to non-diabetic patients when receiving a stent. Using the 
BVMs, research can potentially be conducted in a “normal” and “hyperglycemic” 
environment (without stents) and the results were compared against one another.  
 
Objectives: 
 
The main goals objectives of the experiments performed are as follows: 
 
 Develop and characterize a hyperglycemic environment for the BVM. 
 
  Determine target hyperglycemic values 
 
  Establish a diabetic “recipe,” amount of glucose in media. 
 
  Establish method to measure hyperglycemia in BVMs 
 
Assess a normal and diabetic environment of a coronary artery by incorporating  
 
hyperglycemia in BVMs. 
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Chapter 2: Effects of Glucose on HUVEC Culture 
 
 Before setting up and performing experiments on the BVMs, proper glucose 
concentrations needed to be calculated. A static experiment was performed, using 
hyperglycemic media and HUVECs in petri dishes, to test for different glucose 
concentrations to determine which concentration will be able to keep the cells alive. 
This experiment will also give information on which concentration to use for the 
BVM experiment.  
 Literature review was done on glucose concentrations in diabetic patients, 
and values produced by Mediratta et al. are as followed15: 
• Normal Patients 80-120 mg/dL 
• Moderate 130-160 mg/dL 
• High 180-200 mg/dL 
• Extreme 250 mg/dL 
 
 With this new information, appropriate amounts of glucose needed to be 
added to HUVEC media to obtain the different glucose concentrations. To do this, we 
used the HUVEC media, which contained 500mL EBM2 and EBM2 kit from Lonza. 
After filter sterilizing it, Sigma G6152 D-(+) Glucose from Sigma was added to the 
media. Note that the cell media does not contain the same properties as blood. 
• Control – Normal HUVEC media 
o 20 mL of HUVEC media 
• Low concentration – 0.01 g/mL 
o 20 mL of HUVEC media + 0.2 g of glucose 
• Moderate concentration – 0.014 g/mL 
o 20 mL of HUVEC media + 0.28 g of glucose 
• High concentration – 0.019 g/mL 
o 20 mL of HUVEC media + 0.38 g of glucose 
• Extreme concentration – 0.025 g/mL 
o 20 mL of HUVEC media + 0.5 g of glucose 
 
 *The amount of glucose does not include
media. The amount listed was in addition to the base media formulation.
 
 To test that these concentrations were indeed correct, a 
used. Using the glucose monitor, the test strips were submerged into the HUVEC 
media and glucose solution after a thorough mixing. 
using an autoclave at 121oC for thirty minutes
concentrations.  
 
Figure 4: Glucose meter to determine proper concentrations
 Once the proper concentrations were determined, the next step was to add 
the glucose/media solution to HUVEC
increased glucose concentration. 
 From this static experiment, HUVEC characteristics were determined in the 
presence of increased glucose concentration
contained the same glucose concentration in each well with the same cells. The 
results were consistent with each other; the different concentrations had the same 
effects on the cells from the different plates. There were not any contamination 
 the amount of glucose present in the base 
glucose monitor was 
Then, the media was sterilized 
. All solutions were the pro
 
 
s and evaluate how the cells respond to 
See Appendix A for protocol. 
s. The two plates used were identical, 
12
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issues. Using an inverted light microscope with a camera, the results are as follows 
from 24, 48, 72, 96, 120 hours. The images presented are for day 1 and day 5, the 
beginning and end of the experiment. 
For normal concentration, the control: 
 
Figure 5: Day 1 with normal concentration 
 
Figure 6: Day 5 with normal concentration 
No glucose was added, but still ended up with significant cell death due to lack of 
nutrients by day 5. 
 
For low concentration, 100 mg/dL: 
 
Figure 7: Day 1 of low concentration 
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Figure 8: Day 5 of low concentration 
Low glucose concentration had minimal effect on cell death. 
 
 
For medium concentration, 140 mg/dL: 
 
Figure 9: Day 1 of medium concentration 
 
Figure 10: Day 5 of medium concentration 
Medium glucose had an increased amount of cell death (decreased proliferation)  
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For high concentration, 190 mg/dL: 
 
Figure 11: Day 1 of high concentration 
 
Figure 12: Day 5 of high concentration 
High glucose had a high cell death rate, lack of proliferation, and cellular  
 
morphology seemed to change. 
 
For extreme concentration, 250 mg/dL: 
 
Figure 13: Day 1 of extreme concentration 
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Figure 14: Day 5 of extreme concentration 
Extreme glucose concentration had a high cell death rate, lack of proliferation,  
 
morphology seemed to change just like the high glucose concentration.  
 
 It is apparent that an increase in glucose concentration in the HUVEC media 
had an effect on HUVECs, showing an apparentdecrease in cell proliferation, change 
in cellular morphology, and increase in cell debris. The “age” (the passage of the 
cells) could have also played a role in how the cells reacted to the glucose. The 
concentration that seemed most appealing to use in the BVM set up would be 
somewhere between low and medium concentrations. A concentration like 
120mg/dL would be the best to use, which is 6 g for 500 mL of media. It would be 
the best concentration to use because it did not have much cell death. 
 
 
 
 
 
 
 
 
 
 
 
 
 17
Chapter 3: Hyperglycemic Blood Vessel Mimic 
 
 As noted in the introduction, diabetic patients react differently toward stent 
implantation as compared to “normal” patients. There is a higher risk of restenosis 
with diabetic patients.16 Experiments were performed using the already existing 
BVM that previous students have developed, using a few modifications, to test the 
hypothesis that hyperglycemia has an effect on HUVECs in a BVM. The modifications 
were changing the HUVEC media to incorporate the different glucose concentration 
and compare it to a normal concentration to determine if there is a difference in 
HUVEC characteristic. See Appendix B for protocol for experiment performed. 
 
 
Figure 15: BVM set up with biochamber, pump, and reservoir. 
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Figure 16: Biochamber with the ePTFE grafts and media. 
 
To analyze the results: bisbenzimide (BBI) was used for en face evaluation and 
histology was performed for cross-sectional assessment. See Appendix C for BBI 
protocol, and Appendix D for histology protocol. 
 
 
Results from Hyperglycemic BVM experiment: 
 
 Using BBI and histology evaluation, images were obtained to identify and 
analyze if increased glucose concentration played a role in HUVEC characteristics 
during a BVM experiment. There results are as follows: 
 
 
Figure 17: BBI image of a normal vessel after 1 day. 
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Figure 18: Histology image of a normal vessel after 1 day. 
 
 These images show that the normal vessel after one day had a minimal lining 
of HUVECs around the lumen of the scaffold. This was used as a control to compare 
against the one day hyperglycemic vessel. 
 
 
Figure 19: BBI image of a hyperglycemic vessel after 1 day. 
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Figure 20: Histology image of a hyperglycemic vessel after 1 day 
 These images show that after one day, the increased glucose concentration in 
the media potentially affected the HUVECs slightly. There seems to be more section 
on the vessel with less cells, seen on the BBI images. Also there are small gaps in the 
lining on the histology image. 
 
 
Figure 21: BBI image of a normal vessel after 3 days. 
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Figure 22: Histology image of a normal vessel after 3 days. 
 
 These images of the normal vessels after 3 days showed a confluent lining as 
seen in the histology images (slightly more confluent than at day one). The BBI 
image also shows an abundance of cells on the surface of the scaffold, though there 
are some patches of no cells. 
 
 
Figure 23: BBI image of hyperglycemic vessel after 3 days. 
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Figure 24: Histology image of hyperglycemic vessel after 3 days. 
 
 These images show that increased glucose concentration in the media may 
be detrimental to the characteristics of the HUVECs. The BBI images showed less 
proliferation of the cells as compared to the BBI image of the 3 day normal vessel. In 
the histology image, it does not have a confluent lining around the inner lumen of 
the scaffold and it seems to be as if the cells were group/clumping together.  
 
Conclusion about findings: 
 
 For the vessels at 1 day, for both the normal and hyperglycemic, they showed 
minimal cell coverage throughout the scaffold. The results were similar between the 
two, but the hyperglycemic vessel was not quite as confluent as the normal vessel in 
the BBI and histology images. 
 For the vessels at 3 days, the normal and hyperglycemic vessels showed 
slightly more cell coverage across the scaffold. But after 3 days for the 
hyperglycemic vessel, there appeared to be a decrease in cell density, and it 
appeared as if the cells were balling/clumping up around the inner lumen of the 
scaffold. 
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 These results indicate that glucose concentration affects cellular 
characteristics and are consistent with the results from the static experiment of 
adding media with different concentrations of glucose to cells.  
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Chapter 4: Discussion and Conclusion 
 
 Tissue engineering is an emerging field that has potential for novel and 
unmatched medical therapies and treatment. There is also a field of tissue 
engineering that has another form of application, an application to utilize tissue 
engineered constructs for in-vitro evaluation of medical devices and therapies. In 
vitro blood vessel mimics were created to perform bench top testing that can be 
used to test for vascular disease treatments and intravascular devices. The BVM 
could minimize the development time for emerging technologies and be more cost 
efficient. The blood vessel mimic incorporated in this study was a combination of 
previous experiments, but incorporating increased glucose concentrations.  
 For future work, it would be helpful to perform another static experiment 
with the different glucose concentrations compared to normal concentration (with 
the possibility of performing it concurrently with the BVM set up). This next 
experiment should perform a live/dead stain to determine if the cells are actually 
alive. This would help determine if the increased glucose concentration actually kills 
the cells.  
 Another BVM set up could also be performed with normal HUVEC media in 
the reservoir first, before switching to the hyperglycemic media. It will be known 
that the cells are given the nutrients needed to survive, and switching the media to 
have 3, 4, and 5-day time points would show if the glucose has the same affect as 
being first exposed to the cells. The first three days will have the normal media. 
There is also the possibility to apply a more diabetic condition to the BVM such as 
geometry, flow rate, etc. Blood flow rate in diabetic patients is different that normal 
 25
patients. Increased blood glucose levels and large fluctuations in these levels are 
associated with an increased incidence of diabetic retinopathy and are known to 
affect retinal hemodynamics in diabetic patients.17 In a study conducted, the total 
retinal volumetric blood flow rate in diabetic patients was significantly larger than 
normal by 23%.18 The results also showed larger-than normal veins in diabetic 
patients.18 
 Overall, the work complete indicates that glucose concentration has an effect 
on HUVECs in culture which can bpotentially provide a model for stent implantation 
in a diabetic patient as compared to a normal patient.  
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Appendix A 
 
Static Experiment to Test the Effects of the Different Concentrations of 
Hyperglycemic Media on HUVECs Protocol. 
 
• Thaw out cells. Taking the frozen 1mL solution and placing it into the water 
bath until thawed. Under the hood, adding 12 mL HUVEC media to a T75 
flask and then adding the 1 mL cells solution. Place in 37oC incubator 
overnight. 
• For passing the cells the next day, obtain the T75 and pass it 1:3. Aspirate the 
media in the flask using the vacuum pump, followed by rinsing with DCF-PBS 
and then aspirate again. Add 3 mL of trypsin after it had been thawed and 
vortexed and let sit for approximately 2 minutes. Apply force to the flask if 
necessary to remove the cells from the surface. Deactivate with 5 mL of 
HUVEC media and then mix. Put all 8 mL in a prepared T225 flask that has 30 
mL of HUVEC media (total of 38 mL of cell solution). Place in incubator for 2 
days. 
• After 2 days, take the T225 flask and aspirate off the cell solution media using 
the vacuum. Then rinse with DCF-PBS and aspirate again. Add 9 mL of 
trypsin after it had been thawed and votrexed and let it sit for approximately 
3 minutes. Apply force to the flask if necessary to remove the cells from the 
surface. Deactivate with 9 mL of HUVEC media and then mix. Place 9 mL of 
cell solution into 1 T225 flask that is prepared with 30 mL HUVEC media and 
the another 9 mL of cell solution into another T225 flask that is prepared 
with another 30 mL HUVEC media. Place in incubator for 3 days. 
• Before the initial set up experiment, place 20 mL HUVEC media into 50 mL 
tubes (4 times, one for each glucose concentration). Add the corresponding 
glucose amount to each labeled tube and mix thoroughly Filter sterilize 
media using a 5 µm filter and syringe into another 50 mL tube. Place in 
incubator until ready to start the experiment. 
• Obtaining two 6-well plates, added the cell solution into each well, one T225 
for each plate. For each T225 flask, aspirated the cell solution, rinsed with 
DCF-PBS, added 9 mL trypsin, deactivated with 9 mL HUVEC media, mixed, 
and then added 3 mL solution for each well. Placed in incubator overnight. 
• Obtain the two 6-well plates with the HUVEC and the HUVEC media with 
different concentrations of glucose. Correctly mark where each concentration 
will be. Add 5 mL of each concentration to each well. Take a picture of each 
well and document findings. Place back in incubator overnight (or intended 
time point). 
• For each intended time point, take plates out of incubator and record 
findings, pictures and description. If anytime points are longer than 3 days, 
be sure to change the media (correct media in each well!). 
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Appendix B 
 
Hyperglycemic Blood Vessel Mimic Experiment Protocol 
 
For preparation one week prior to the set up: 
 
• Gas sterilize the biochambers, lids, 2-port reservoirs, and the necessary 
tubing and fittings at the vet clinic (this must be done over the weekend 
because of dangerous fumes). 
• Determine the number of cells needed and the passage schedule to obtain 
target cells. Thaw the cells and pass them according to schedule. 
• Obtain ePTFE grafts, mount them on the proper fittings, and suture them 
onto fittings. 
• Autoclave ePTFE grafts, flasks for degassing media, and forceps that are in 
the proper packaging. 
 
Preparation the day before the set up: 
 
• Make the necessary media 
o HUVEC media 
 500 mL EBM2 and kit from Lonza 
o HUVEC media with added glucose 
 500 mL EBM2 plus 0.012 g/mL (2 g for 500 mL of media) 
 Autoclaved base media with glucose at Applied Biotechnology 
Institute (30 minute cycle) 
 After media has cooled, add kit from Lonza after media has 
cooled down 
o Bioreactor media 
 500 mL M199, 56 mL FBS, 5 mL L-glutmine, 5 mL P/S, 0.6 mL 
Fungizone, 2.8 mL Hepes 
o Conditioning media 
 500 mL M199, 83 mL FBS, 5 mL P/S, 0.6 mL Fungizone. 
• Denucleate ePTFE grafts (using filtered EtOH) after autoclave 
o Start my degassing conditioning media in the flask with the vacuum 
pump attachment. Degass for approximately 30 minutes 
o Take autoclaved ePTFE grafts and add them to 70% EtOH for 15 
minutes. Each graft will be in a separate 15 mL tube. 
o Transfer grafts, using sterile forceps, to 100% EtOH for 15 minutes or 
until grafts turn “clear”. Agitate if necessary. Each graft will be in a 
separate 15 mL tube. 
o Take degassed conditioning media and add to 15 mL tubes. 
o Using sterile forceps, take graft from 100% EtOH and transfer it to the 
degassed media tubes.  
o Place in 35oC incubator overnight. 
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Set up day:  
 
• Warm up bioreactor media, conditioning media, and HUVEC media. 
• Fill the biochambers with the bioreactor media. Make sure that the fittings 
are closed off. 
• Once the biochambers are filled to the appropriate level, insert the sterile 
grafts into the biochamber. Be sure to keep everything sterile. 
• Using sterile gloves, attach the fittings from the grafts onto the biochamber 
fittings. 
• Number the corresponding biochamber lids with the correct number using a 
tape and marker. 
• Using a syringe filled with conditioning media, attach it to the fitting 
connected to the biochamber and flush the lumen to prime the graft. Clamp 
the lumen and continue to prime the graft. Repeat for all of the grafts. 
• Add conditioning media to the two port reservoirs, enough to where the 
tubing is submerged. Connect the fittings to the biochamber fittings.  
• Turn on the CO2 and prep the incubator (clean shelves and plug in the pump). 
• Once everything is prepped, bring the biochamber with the reservoir into the 
incubator and attach it to the pump. Allow the media to flow through the 
lumen first to remove air bubbles, and then clamp the lumen to allow for 
transmural flow for 10 minutes at 150-rpm. 
• Leave the primed biochambers in the large incubator until the cells are ready 
to sod the grafts. 
• Prep the 2-port reservoir with HUVEC media with the different glucose 
concentrations (make sure they correspond with the appropriate numbers). 
Prepare one for each vessel and make sure that the drip is visible and the 
outlet is submerged in the media. Clamp the tubing and leave in the 
incubator until the cell-sodding step. 
• Harvest the cells from the T225s. 
o Aspirate media using vacuum 
o Rinse with DCF-PBS and aspirate 
o Apply the appropriate amount of trypsin, agitate and mix to make 
sure all the cells are removed from the surface. 
o Deactivate with HUVEC media 
o Take the cell solution and add to 50 mL tube 
o Centrifuge solution on setting 4 for 4 minutes 
o Aspirate supernatant, do not aspirate the pellet at the bottom 
o Resuspend the pellet using appropriate amount of HUVEC media. 
o Prepare one trough of HUVEC media and one trough with the cell 
solution. 
• Remove biochambers and reservoirs from incubator and place them in the 
hood, prep for cell sodding. 
• For each vessel: 
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o Prime each graft by injecting 5 mL of HUVEC media using a syringe 
while capping off the proximal stopcock so the fluid will not flow back 
into the reservoir. Close off the stopcock and remove the syringe. 
o Using a syringe, take up 4 mL of the cell solution and attach it to the 
stopcock. Inject the cell solution at a very moderate rate. Once it is 
about to finish, cap off stopcock and detach the syringe.  
o Chase the cells with 4 mL HUVEC media using the syringe. 
o Replace the old reservoir with the new HUVEC media with different 
glucose concentrations. Be sure to tighten the reservoir caps. 
o Move the BVM system into the incubator and attach it to the pump. 
• Maintain transmural flow at 10 rpm for 30 minutes. 
• After 30 minutes, stop transmural flow and maintain luminal flow at 15 rpm 
for 24 hours. 
• If necessary, remove BVM at 24 hours, and adjust the luminal flow 10-15 rpm 
at a time until it reaches 90 rpm. 
• Replace reservoir media every 3rd day if the experiment runs more, and be 
sure to check the CO2 level.  Make sure that none of the bioreactors are 
leaking media. 
• Take down each vessel at designated time points and cut the ePTFE grafts off 
the fitting, and using sterile procedure, place them into a tube filled with 
histochoice. 
• Leave in histochoice until ready for evaluation.  
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Appendix C 
 
BBI Evaluation protocol (by Dalton Chavez): 
 
• Begin by wrapping a nonsterile 15 mL tube in foil, not allowing light in. 
Thoroughly label all tube for all the samples. 
• Make the BBI solution, be sure to always keep the stock solution wrapped in 
foil to keep light out. 
• Use a small stock solution (acquired in the refrigerator and dilute 1:1000 
with milli-Q water (10 µl stock solution in 10 mL water). Use the pipette aid 
for the milli-Q water, and then spray it down with EtOH before replacing it. 
Mix the solution by inverting it. 
• The each sample using a blade, being careful not to disrupt the cell lining 
inside the lumen (squeezing, touching, and scraping can disrupt the lining 
and ruin the experiment. 
• Using clean forceps, place the ePTFE grafts in the corresponding 15 mL tubes 
that contain the BBI solution. Carefully keep track of samples, and leave in 
BBI solution for at least 15 minutes. Left in longer is better, but do not leave 
in too long or cells will get bleached out. 
• Put away extra stock solution and clean up preparation area. 
• With the permission or help from Dr. Cardinal, use the fluorescent 
microscope to obtain en face images. Take forceps and kimwipes to use at the 
microscope. 
• When at the microscope, use the following steps to obtain images: 
o Log into notebook (fluorescence, initials, date, time, and lamp hours). 
o Turn turret to setting 4. 
o Turn on Olympus lamp (green switch) 
o Turn on Optiscan wheel (black switch) 
o Turn on the camera (black switch) 
o Set filter wheel 1 to 1, and set filter wheel 2 to 1. 
o Open the shutter 
o Set prior keypad to shutter S1. 
o Dial objectives to desired magnification (typically 4x and 10x for BBI 
images). 
o Set thin bar icon of eye and camera 
o Sign into the computer by clicking Kristen’s account (password can be 
obtained from Kristen). 
o Click QCapture Pro (on desktop) 
o Click camera icon at top of QCapture Pro window. 
o Place slide onto microscope, then place the sample to top of it. 
o Manually adjust microscope to clarify the image. 
o If scaffold is too wet, carefully blot end of scaffold on kimwipe. 
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o Take pictures, and save to desired folder. Label samples with 
information, initials, and magnification. 
o Once finished, log out, shit down system by switching off Olympus 
lamp, Optiscan wheel, and camera.  
o Log out of notebook. 
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Appendix D 
 
Hematoxylin and Eosin (H&E) Staining Protocol 
 
For acquisition of histology images: 
 
Hematoxylin and Eosin ePTFE staining protocol: 
 
• Place desired samples in cassettes and set them in histochoice. 
• With the help of a laboratory technician, place samples in processor and run 
it for 14 hours. 
• Remove samples and embed them into wax. 
• Samples are now ready for sectioning and staining. 
• To begin sectioning, start by preparing the area. 
o Put on gloves, eye protection, and laboratory aprons. 
o Place the blocks in the refrigerator. 
o Turn on the oven. 
o Turn on the small water bath by simply plugging it in. Do not adjust 
the knob, and add distilled water. 
o Place blade on the microtome. The blades can be found in the box next 
to the microtome. Be careful, the blades are very sharp. Do not touch 
the blade with anything, it will nick the blade and make it useless. 
• To begin sectioning: 
o Take block from the refrigerator and secure it in the microtome 
clamp. 
o Adjust the levers to make sure the block face flesh is against the blade. 
o Cut the sections of tissue blocks at 7 µm. 
o Use the forceps to carefully place sections into the water bath. 
o Pick up sections with a slide. The white part of the slide has a rough 
and smooth side. Place sections only on the rough side. 
o Using a pencil, label the slide with the following information: block 
number, date, and initials. 
o Place slides on the drying rack. 
o Repeat sectioning to obtain 2-3 good slides. 
• To begin staining: 
o Place the dry slides into staining rack (the small steel holder). 
o Put the staining rack in the oven for 10 minutes or until the wax is 
clear. 
o While the slides are in the oven, clean the microtome station by 
returning the blade, turn off the microtome, unplugging the water 
bath, and disposing of the water. 
o Pull the staining rack out of the over and allow it to cool for 5 minutes 
(until some wax begins to show again). 
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o During the waiting period, prepare the staining station by filling 
dishes and organizing appropriately. 
o Then begin the staining process. The rack will be dipped into each of 
these staining dishes for the given time shown in the following order: 
 5 minutes – Xylene (in hood) 
 5 minutes – Xylene (in hood) 
 2 minutes – 100% EtOH  
 2 minutes – 100% EtOH  
 2 minutes – 95% EtOH  
 1 minute – Air Dry 
 4 minutes – Hematoxlin 
 1 minute – Distilled Water 
 30-45 seconds – Clarifier 
 1 minute – Distilled Water 
 1 minute – Bluing 
 1 minute – Distilled Water 
 1 minute – 95% EtOH 
 1 minute 30 seconds – Eosin 
 1 minutes – 100% EtOH  
 1 minutes – 100% EtOH  
 5 minutes – Xylene (in hood) 
 5 minutes – Xylene (in hood) 
 
• To begin cover slipping, performed in the hood after staining is complete: 
o Pick up the slide with hemostats. Be careful because there is still 
xylene on the slides 
o Put a thin line of mounting glue along the long edge of one slide 
o Take cover slip and place it slowly in the slide. Be sure not to slide 
over the sample and damage it, and make sure there are no bubbles 
and the sample is fully covered with the mounting glue. 
o Repeat process for each slide, and let them dry on the tray. 
 
• To begin analyzing these samples (protocol by Dalton Chavez) 
o With the permission or help from Dr. Cardinal, use the white-light 
microscope to obtain the images of the samples mounted on slides.  
o Log into notebook with the following information: white, initials, date, 
time, and lamp hours. 
o Turn turret to setting 1. 
o Turn on Optiscan wheels (black switch). 
o Turn on the camera (black switch). 
o Set filter wheel 2 to 5. 
o Open the shutter. 
o Set prior keypad to shutter S1. 
o Turn on the white light (black switch on the side of the microscope 
are). 
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o Dial objectives to desired magnification (typically 10x for histology 
images of cell sodded scaffolds). 
o Set the thin bar to icon of eye and camera. 
o Sign into computer by clicking Kristen’s account (password can be 
obtained from Kristen). 
o Click QCapture Pro (on desktop). 
o Click camera icon at top of QCapture Pro window. 
o Place slide on the microscope. Use the joystick to move sample under 
microscope lens. Use the dial on base of microscope to adjust 
exposure of live image. 
o  Use course focus and fine focus on base of microscope to clarify live 
image. 
o Refocus image if desired. Click “Snap” to take pictures. Save to desired 
folder, and label samples. 
o Repeat this for the desired samples. 
o Quit QCapture Pro and log out of computer. 
o Shut down microscope by switching off Optiscan wheels, camera and 
white light. 
o Log out of notebook. 
 
